|
2024
|
Invention
|
Anti-o1 antibodies and uses thereof.
The present disclosure provides binding proteins (e.g., ant... |
|
|
Invention
|
Pd-1/tim-3 binding proteins for treatment of nsclc and chl.
The disclosure relates to methods of... |
|
|
Invention
|
Pd-1/tim-3 binding proteins for treatment of nsclc and chl. The disclosure relates to methods of ... |
|
|
Invention
|
Treatment of corticosteroid dependent asthma with anti-tslp antibody. The present disclosure rela... |
|
|
Invention
|
Pd-1/tigit binding proteins for cancer treatment.
The disclosure relates to methods of treating ... |
|
|
Invention
|
Pd-1/tigit binding proteins for cancer treatment. The disclosure relates to methods of treating c... |
|
|
Invention
|
Steap2 directed t-cell engagers and compositions thereof. Provided are T cell engaging molecules ... |
|
|
Invention
|
Steap2 antibody drug conjugates and uses thereof. The present disclosure relates to binding molec... |
|
|
Invention
|
Optimized cd3 antigen binding domains.
The present disclosure relates to antibodies or fragments... |
|
|
Invention
|
Optimized cd3 antigen binding domains. The present disclosure relates to antibodies or fragments ... |
|
|
Invention
|
Trispecific engineered antibodies.
Provided herein are trispecific antibodies containing three a... |
|
|
Invention
|
Bispecific engineered antibodies.
Provided herein is a multispecific antibody containing two ant... |
|
|
Invention
|
Bispecific engineered antibodies. Provided herein is a multispecific antibody containing two anti... |
|
|
Invention
|
Trispecific engineered antibodies. Provided herein are trispecific antibodies containing three an... |
|
|
Invention
|
Engineered antibodies.
Provided herein are multispecific antibodies containing a lambda charge p... |
|
|
Invention
|
Engineered antibodies. Provided herein are multispecific antibodies containing a lambda charge pa... |
|
|
Invention
|
Fluidic mixer unit device for nanoparticle production. A device 100 for producing nanoparticles i... |
|
|
Invention
|
Antibody directed against s. aureus clumping factor a (clfa).
The present disclosure is directed... |
|
|
Invention
|
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concen... |
|
|
Invention
|
Bispecific pd-1 and tigit binding proteins and uses thereof.
The disclosure relates to binding p... |
|
|
Invention
|
Treatment of chronic rhinosinusitis with anti-tslp antibody. The present disclosure, relates, in ... |
|
|
Invention
|
Neutralizing anti-influenza a antibodies and uses thereof.
The invention relates to antibodies a... |
|
|
Invention
|
Bcma monoclonal antibody-drug conjugate.
The disclosure is directed to an antibody-drug conjugat... |
|
2023
|
Invention
|
Adeno-associated virus production platform. Provided herein is a novel rAAV-based HSV production ... |
|
|
Invention
|
Immune repertoire mining.
The present invention provides a method for producing encapsulated nat... |
|
|
Invention
|
Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18.... |
|
|
Invention
|
Methods for determining treatment for cancer patients.
Methods for determining treatments for ca... |
|
|
Invention
|
Neutralizing anti-influenza b antibodies and uses thereof.
The invention relates to antibodies a... |
|
|
Invention
|
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic pro... |
|
|
Invention
|
Combination therapies for treatment of cancer.
Provided herein are methods of treating cancer in... |
|
|
Invention
|
Combination therapies for treatment of cancer. Provided herein are methods of treating cancer in ... |
|
|
Invention
|
Methods for expanding t cell populations.
Provided herein are methods for manufacturing, expandi... |
|
|
Invention
|
Methods for expanding t cell populations. Provided herein are methods for manufacturing, expandin... |
|
|
Invention
|
Methods for predicting the clinical outcome of patients suffering from chronic obstructive pulmon... |
|
|
Invention
|
Method and molecules.
The present invention provides a bioconjugation method and compounds for u... |
|
|
Invention
|
Treatment methods using ctla-4 and pd-1 bispecific antibodies.
The present disclosure provides m... |
|
|
Invention
|
Treatment methods using ctla-4 and pd-1 bispecific antibodies. The present disclosure provides me... |
|
|
Invention
|
Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical c... |
|
|
Invention
|
Method of purifying albumin-fusion proteins.
The present invention relates to a method of purify... |
|
2022
|
Invention
|
Method of treating influenza a.
Provided herein are methods for treating, reducing or preventing... |
|
|
Invention
|
Purification of antibodies.
The disclosure provides methods for the isolation, separation, and p... |
|
|
Invention
|
Anti-steap2 chimeric antigen receptors and uses thereof.
The disclosure provides chimeric antige... |
|
|
Invention
|
Anti-il-13 antibody formulation.
The present invention relates to a pharmaceutical composition c... |
|
|
Invention
|
Modified fcrn binding fragments with improved half-life.
The present disclosure relates to modif... |
|
2021
|
Invention
|
Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy.
This disclosure re... |
|
|
P/S
|
Pharmaceutical preparations and substances for treatment of respiratory diseases and disorders |
|
|
Invention
|
Bispecific binding proteins and uses thereof. The disclosure generally provides proteins that bin... |
|
|
Invention
|
Detergent and method for purifying a biotherapeutic.
Provided herein is an environmentally compa... |
|
|
Invention
|
Formulations of anti-endothelial lipase antibodies. Provided are formulations of an antibody that... |
|
2019
|
Invention
|
Branched moiety for use in conjugates.
A tri-functional linker moiety: formula (I), where X and ... |
|
2012
|
P/S
|
Vaccines |
|
2009
|
P/S
|
Influenza vaccines for humans. |
|
|
P/S
|
Vaccines against flu. |
|
2005
|
P/S
|
Vaccines for use by humans in the prevention and treatment of viral infections. |
|
2004
|
P/S
|
Pharmaceutical preparations and substances for health care and medical clinical use. Health care ... |
|
|
P/S
|
Pharmaceutical preparations and substances for heath care and medical clinical use. Health care s... |
|
|
P/S
|
Humanized monoclonal antibody against respiratory syncytial virus for scientific research use. Hu... |
|
2003
|
P/S
|
VACCINES |
|
1998
|
P/S
|
Pharmaceutical, veterinary and sanitary preparations and substances; vitamin preparations and vac... |
|
|
P/S
|
Humanized monoclonal antibody against respiratory syncytial virus. |
|
1997
|
P/S
|
A humanized monoclonal antibody against respiratory syncytial virus. |
